U.S. lawmakers question Mylan’s Medicaid EpiPen rebates
Two key U.S. congressional committee members on Friday called for an investigation into whether Mylan NV, under fire for raising the price of its EpiPen device, overcharged the government's low-income healthcare program for the allergy treatment. In a letter to the secretary of the Department of Health and Human Services, Senator Ron Wyden and Representative Frank Pallone, both Democrats, seek clarification of whether EpiPen was classified as a generic, “non-innovator” drug, or a brand-name drug by the Medicaid program. Under current law, branded drugs, and generic drugs available from a single source, are required to pay a rebate amount of at least 23.1 percent of the average manufacturer price.
More here:
U.S. lawmakers question Mylan’s Medicaid EpiPen rebates
About Author
U.S. lawmakers question Mylan’s Medicaid EpiPen rebates
Two key U.S. congressional committee members on Friday called for an investigation into whether Mylan NV, under fire for raising the price of its EpiPen device, overcharged the government's low-income healthcare program for the allergy treatment. In a letter to the secretary of the Department of Health and Human Services, Senator Ron Wyden and Representative Frank Pallone, both Democrats, seek clarification of whether EpiPen was classified as a generic, “non-innovator” drug, or a brand-name drug by the Medicaid program. Under current law, branded drugs, and generic drugs available from a single source, are required to pay a rebate amount of at least 23.1 percent of the average manufacturer price.
View original here:
U.S. lawmakers question Mylan’s Medicaid EpiPen rebates
About Author
